Boston Scientific announced that it has entered into a definitive agreement with Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, to sell its BTG Specialty Pharmaceuticals business for $800 million in cash.
SAB Biotherapeutics (SAB) as part of Operation Warp Speed, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) have awarded SAB $57.5 million in expanded scope for its DiversitAb Rapid Response Antibody Program contract for the manufacturing of SAB-185, the company’s clinical stage therapeutic candidate for COVID-19.
Dr. Reddy’s Laboratories has entered into a definitive agreement with Glenmark Pharmaceuticals to acquire, subject to completion of certain precedent actions and closing activities, brands Momat Rino (for Russia, Kazakhstan and Uzbekistan), Momat Rino Advance (for Russia), Momat A (for Kazakhstan and Uzbekistan), Glenspray and Glenspray Active (for Ukraine), along-with rights to the trademarks, dossiers and patents for the territories mentioned.
The European Commission (EC) has approved an agreement to purchase an initial 80 million doses of mRNA-1273, a vaccine candidate against Covid-19, from Moderna.
Moderna, a new generation of transformative medicines for patients, today announced a supply agreement with the UK government to supply mRNA-1273, its Covid-19 vaccine candidate, beginning in March 2021 if it is approved for use by UK regulatory authorities.
Mylan and Pfizer announced that the U.S. Federal Trade Commission (the “FTC”) accepted a proposed consent order, which concludes the FTC’s review of the proposed combination of Mylan and Pfizer’s Upjohn Business.
Cheplapharm Arzneimittel has agreed to acquire commercial rights of heart failure and hypertension drugs from AstraZeneca in a deal valued at around $400m.
Eli Lilly has secured a $375m contract from the US government to supply 300,000 doses of its bamlanivimab (LY-CoV555) 700mg investigational neutralising antibody to fight against Covid-19.
GlaxoSmithKline (GSK) and Sanofi have entered into a statement of intent with Gavi to supply 200 million doses of their adjuvanted recombinant protein-based Covid-19 vaccine to the COVAX Facility.
Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced a supply agreement with the Ministry of Public Health of Qatar for mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support the Ministry’s ongoing efforts to secure early access to a safe and effective COVID-19 vaccine for the people of Qatar.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.